An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction
- 1 August 2001
- journal article
- clinical trial
- Published by Elsevier in Clinical Therapeutics
- Vol. 23 (8) , 1260-1271
- https://doi.org/10.1016/s0149-2918(01)80105-3
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction.European Urology, 2001
- Apomorphine: an update of clinical trial resultsInternational Journal Of Impotence Research, 2000
- Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunctionUrology, 2000
- Structure and function of dopamine receptorsPublished by Elsevier ,2000
- Oral pharmacotherapy for erectile dysfunction: current perspectivesUrology, 1999
- Domperidone: A Peripherally Acting Dopamine2-Receptor AntagonistAnnals of Pharmacotherapy, 1999
- THE EPIDEMIOLOGY AND PATHOPHYSIOLOGY OF ERECTILE DYSFUNCTIONJournal of Urology, 1999
- The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunctionUrology, 1997
- Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging StudyJournal of Urology, 1994
- NIH Consensus Conference. Impotence. NIH Consensus Development Panel on ImpotenceJAMA, 1993